NZ591415A - Haemophilus influenzae type B - Google Patents

Haemophilus influenzae type B

Info

Publication number
NZ591415A
NZ591415A NZ591415A NZ59141506A NZ591415A NZ 591415 A NZ591415 A NZ 591415A NZ 591415 A NZ591415 A NZ 591415A NZ 59141506 A NZ59141506 A NZ 59141506A NZ 591415 A NZ591415 A NZ 591415A
Authority
NZ
New Zealand
Prior art keywords
haemophilus influenzae
influenzae type
protein
sequence
making
Prior art date
Application number
NZ591415A
Other languages
English (en)
Inventor
Vega Masignani
Rino Rappuoli
Herve Tettelin
Original Assignee
Novartis Vaccines & Diagnostic
Craig J Venter Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Craig J Venter Inst Inc filed Critical Novartis Vaccines & Diagnostic
Publication of NZ591415A publication Critical patent/NZ591415A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Materials For Photolithography (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ591415A 2005-03-30 2006-03-30 Haemophilus influenzae type B NZ591415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66792105P 2005-03-30 2005-03-30
NZ562381A NZ562381A (en) 2005-03-30 2006-03-30 Haemophilus influenzae type B

Publications (1)

Publication Number Publication Date
NZ591415A true NZ591415A (en) 2012-10-26

Family

ID=37087506

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ591415A NZ591415A (en) 2005-03-30 2006-03-30 Haemophilus influenzae type B
NZ562381A NZ562381A (en) 2005-03-30 2006-03-30 Haemophilus influenzae type B

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ562381A NZ562381A (en) 2005-03-30 2006-03-30 Haemophilus influenzae type B

Country Status (11)

Country Link
US (4) US20100034822A1 (enExample)
EP (1) EP1871888A4 (enExample)
JP (1) JP2008538183A (enExample)
CN (1) CN101687025A (enExample)
AU (1) AU2006235045A1 (enExample)
BR (1) BRPI0609460A2 (enExample)
CA (1) CA2602665A1 (enExample)
MX (1) MX2007012057A (enExample)
NZ (2) NZ591415A (enExample)
RU (1) RU2007139915A (enExample)
WO (1) WO2006110413A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
JP2014516028A (ja) * 2011-05-11 2014-07-07 リースベック ヘルスケア スウェーデン アクティエボラーグ ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP4014966A1 (en) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
AR090303A1 (es) * 2013-03-11 2014-11-05 Consejo Nac Invest Cient Tec Polipeptido mutado, cepa de bacterias que lo comprende y metodos para detectar diferentes cationes metalicos simultaneamente
US9868777B2 (en) 2013-06-10 2018-01-16 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
CN107072946B (zh) 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201508860D0 (en) 2015-05-22 2015-07-01 Nat Univ Ireland Diagnostic method
US11401520B2 (en) 2016-10-21 2022-08-02 The Research Foundation For The State University Of New York Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3931206A1 (en) * 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccines targeting h. influenzae
WO2020243697A1 (en) * 2019-05-31 2020-12-03 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
US11357845B2 (en) * 2019-07-08 2022-06-14 The Trustees Of The University Of Pennsylvania Protein antigens for vaccinating against nontypeable Haemophilus influenzae
KR20230118715A (ko) 2020-10-14 2023-08-11 조지 메이슨 리서치 파운데이션 인코포레이티드 이온화 가능 지질 및 이의 제조 및 사용 방법
AU2021372524A1 (en) * 2020-10-30 2023-05-04 Gen-Probe Incorporated Compositions and methods for detecting influenza a, influenza b, and sars-cov-2
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
US20260124157A1 (en) 2024-08-09 2026-05-07 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US6730827B1 (en) * 1998-07-14 2004-05-04 E. I. Du Pont De Nemours And Company Genes encoding plant adenosine 5′-phosphosulfate reductase
US7365185B2 (en) * 2000-07-19 2008-04-29 Monsanto Technology Llc Genomic plant sequences and uses thereof
KR20020097200A (ko) * 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
CA2517899A1 (en) * 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
GB0315022D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Virulence-associated adhesins
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP2008546390A (ja) * 2005-06-16 2008-12-25 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド 分類不能型インフルエンザ菌の中耳炎単離物の遺伝子

Also Published As

Publication number Publication date
WO2006110413A9 (en) 2010-01-14
EP1871888A4 (en) 2013-08-21
CA2602665A1 (en) 2006-10-19
BRPI0609460A2 (pt) 2010-04-13
US20160024157A1 (en) 2016-01-28
MX2007012057A (es) 2007-11-23
RU2007139915A (ru) 2009-05-10
WO2006110413A2 (en) 2006-10-19
AU2006235045A1 (en) 2006-10-19
JP2008538183A (ja) 2008-10-16
US20140302078A1 (en) 2014-10-09
EP1871888A2 (en) 2008-01-02
NZ562381A (en) 2011-06-30
US20100034822A1 (en) 2010-02-11
CN101687025A (zh) 2010-03-31
US20120093868A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
UA102503C2 (en) Interleukin-13 binding proteins
AU4981101A (en) Subtilisin variants
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
WO2009083968A8 (en) Novel protein
DE60037413D1 (de) Rekombinante adhesin-proteine aus haemophilus influenzae
ATE458037T1 (de) Grosstechnisch geeigneter mikroorganismus
TW200801034A (en) Novel sea lice vaccine
WO2001036478A3 (en) Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides
PL1716169T3 (pl) Podjednostkowe szczepionki przeciwko Ornithobacterium rhinotracheale
DK1863834T3 (da) Polypeptider og nukleinsyrer, der koder disse
ATE556135T1 (de) Neues protein
GB0409559D0 (en) Polypeptide
WO2004065554A3 (en) Human saa3 nucleic acid molecule, protein, and methods of use for same
ATE452141T1 (de) Neue proteine, z.b. zur verwendung für die in- vitro-isolierung und prävention von legionella pneumophila-infektionen
WO2003022990A3 (en) Production of fusion proteins and use for identifying binding molecules
WO2003040394A3 (en) Production of recombinant proteins in vivo and use for generating antibodies
WO2004013281A3 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAR 2016 BY CPA GLOBAL

Effective date: 20130214

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAR 2013 BY FB RICE

Effective date: 20130205

LAPS Patent lapsed